{"id":61065,"date":"2023-12-04T11:08:45","date_gmt":"2023-12-04T02:08:45","guid":{"rendered":"https:\/\/monolith.law\/tr\/?p=61065"},"modified":"2024-03-17T11:06:49","modified_gmt":"2024-03-17T02:06:49","slug":"quasi-drug-advertisement-guidelines","status":"publish","type":"post","link":"https:\/\/monolith.law\/tr\/general-corporate\/quasi-drug-advertisement-guidelines","title":{"rendered":"\u0130la\u00e7 D\u0131\u015f\u0131 \u00dcr\u00fcnlerin Reklam Yay\u0131n\u0131nda Dikkat Edilmesi Gereken K\u0131lavuzlar Nelerdir?"},"content":{"rendered":"\n<p>\u00d6rne\u011fin &#8220;medicinal cosmetics&#8221; gibi \u00fcr\u00fcnlerin \u00fcretimi ve sat\u0131\u015f\u0131, her \u00fcr\u00fcn i\u00e7in Japon Sa\u011fl\u0131k, \u00c7al\u0131\u015fma ve Refah Bakan\u0131&#8217;n\u0131n onay\u0131n\u0131 gerektirir. Bir inceleme s\u00fcrecinden ge\u00e7tikten ve onay al\u0131nd\u0131ktan sonra, \u00fcr\u00fcn\u00fcn\u00fcz\u00fc satmaya haz\u0131r oldu\u011funuzda, daha fazla m\u00fc\u015fteriye ula\u015fmak i\u00e7in genellikle bir web sitesi olu\u015fturur ve ilgili reklamlar yay\u0131nlar\u0131n\u0131z.<\/p>\n\n\n\n<p>Bu nedenle, reklamlar\u0131n\u0131zda ve web sitenizde, onaylanm\u0131\u015f etkin bile\u015fenlerin i\u00e7eri\u011fi ve ne t\u00fcr etkileri oldu\u011fu gibi \u00e7e\u015fitli ifadeler kullanarak \u00fcr\u00fcn\u00fcn\u00fcz\u00fc tan\u0131t\u0131rs\u0131n\u0131z. \u00d6rne\u011fin, bir e-ticaret sitesinin a\u00e7\u0131l\u0131\u015f sayfas\u0131nda (LP), \u00fcr\u00fcn\u00fcn\u00fcz\u00fc \u00e7ekici bir \u015fekilde tan\u0131tan bir a\u00e7\u0131klama yapars\u0131n\u0131z.<\/p>\n\n\n\n<p>Ancak, t\u0131bbi cihazlar genellikle belirli etkin bile\u015fenler i\u00e7erir ve farmakolojik etkileri vard\u0131r. T\u00fcketicilerin yan\u0131lg\u0131lara d\u00fc\u015fmemesi i\u00e7in, hangi t\u00fcr reklamlar\u0131n kabul edilebilir oldu\u011funu belirleyen kurallar yasalarla belirlenmi\u015ftir.<\/p>\n\n\n\n<p>Bu makalede, reklam ifadelerinin hangi kurallarla d\u00fczenlendi\u011fini ayr\u0131nt\u0131l\u0131 olarak a\u00e7\u0131klayaca\u011f\u0131z.<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_53 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/monolith.law\/tr\/general-corporate\/quasi-drug-advertisement-guidelines\/#Ilac_Makinesi_Yasasi%E2%80%99na_Gore_Reklam_Duzenlemeleri\" title=\"\u0130la\u00e7 Makinesi Yasas\u0131&#8217;na G\u00f6re Reklam D\u00fczenlemeleri\">\u0130la\u00e7 Makinesi Yasas\u0131&#8217;na G\u00f6re Reklam D\u00fczenlemeleri<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/monolith.law\/tr\/general-corporate\/quasi-drug-advertisement-guidelines\/#Tanimi_Ilac_Disi_Urunler\" title=\"Tan\u0131m\u0131 \u0130la\u00e7 D\u0131\u015f\u0131 \u00dcr\u00fcnler\">Tan\u0131m\u0131 \u0130la\u00e7 D\u0131\u015f\u0131 \u00dcr\u00fcnler<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/monolith.law\/tr\/general-corporate\/quasi-drug-advertisement-guidelines\/#%E3%80%8C%E5%8C%BB%E8%96%AC%E9%83%A8%E5%A4%96%E5%93%81%E3%80%8Dnin_Reklam_Ifadeleri_Duzenlemesi\" title=\"\u300c\u533b\u85ac\u90e8\u5916\u54c1\u300dnin Reklam \u0130fadeleri D\u00fczenlemesi\">\u300c\u533b\u85ac\u90e8\u5916\u54c1\u300dnin Reklam \u0130fadeleri D\u00fczenlemesi<\/a><ul class='ez-toc-list-level-3'><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/monolith.law\/tr\/general-corporate\/quasi-drug-advertisement-guidelines\/#%E3%80%8CReklam%E3%80%8Din_Tanimi\" title=\"\u300cReklam\u300d\u0131n Tan\u0131m\u0131\">\u300cReklam\u300d\u0131n Tan\u0131m\u0131<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/monolith.law\/tr\/general-corporate\/quasi-drug-advertisement-guidelines\/#Reklami_Duzenlenen_Taraflar\" title=\"Reklam\u0131 D\u00fczenlenen Taraflar\">Reklam\u0131 D\u00fczenlenen Taraflar<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/monolith.law\/tr\/general-corporate\/quasi-drug-advertisement-guidelines\/#Hangi_Ifadeler_%E2%80%9CAbartili%E2%80%9D_Olarak_Kabul_Edilir\" title=\"Hangi \u0130fadeler &#8220;Abart\u0131l\u0131&#8221; Olarak Kabul Edilir?\">Hangi \u0130fadeler &#8220;Abart\u0131l\u0131&#8221; Olarak Kabul Edilir?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/monolith.law\/tr\/general-corporate\/quasi-drug-advertisement-guidelines\/#Ozet\" title=\"\u00d6zet\">\u00d6zet<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ilac_Makinesi_Yasasi%E2%80%99na_Gore_Reklam_Duzenlemeleri\"><\/span>\u0130la\u00e7 Makinesi Yasas\u0131&#8217;na G\u00f6re Reklam D\u00fczenlemeleri<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>\u0130la\u00e7 Makinesi Yasas\u0131, &#8220;\u0130la\u00e7lar, T\u0131bbi Cihazlar vb. \u00dcr\u00fcnlerin Kalitesi, Etkinli\u011fi ve G\u00fcvenli\u011finin Sa\u011flanmas\u0131 Hakk\u0131nda Kanun&#8221; (Showa 35 y\u0131l\u0131 Kanun No. 145) (bundan sonra &#8220;\u0130la\u00e7 Makinesi Yasas\u0131&#8221; olarak an\u0131lacakt\u0131r) olarak bilinir.<\/p>\n\n\n\n<p>\u0130la\u00e7 Makinesi Yasas\u0131, t\u00fcketicilerin g\u00fcvenli \u00fcr\u00fcnleri se\u00e7ebilmesi ve sa\u011fl\u0131klar\u0131n\u0131 koruyabilmesi i\u00e7in reklamlar hakk\u0131nda belirli ifade d\u00fczenlemeleri yapmaktad\u0131r.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote\">\n<p>(A\u015f\u0131r\u0131 Reklamlar vb.) \u0130la\u00e7 Makinesi Yasas\u0131 Madde 66<br> 1. Kimse, ila\u00e7lar, t\u0131bbi cihazlar, kozmetikler, rejeneratif t\u0131p \u00fcr\u00fcnleri vb. hakk\u0131nda, a\u00e7\u0131k veya ima yoluyla, yan\u0131lt\u0131c\u0131 veya abart\u0131l\u0131 ifadeleri reklam yaparak, yazarak veya yaymayamaz.<br> 2. \u0130la\u00e7lar, t\u0131bbi cihazlar, kozmetikler, rejeneratif t\u0131p \u00fcr\u00fcnleri vb. hakk\u0131nda, bir doktor veya ba\u015fka bir ki\u015fi taraf\u0131ndan garanti edildi\u011fi yan\u0131lg\u0131s\u0131na yol a\u00e7abilecek ifadeleri reklam yaparak, yazarak veya yaymak, birinci f\u0131krada belirtilen durumlar\u0131 kapsar.<br> 3. Kimse, ila\u00e7lar, t\u0131bbi cihazlar, kozmetikler, rejeneratif t\u0131p \u00fcr\u00fcnleri vb. hakk\u0131nda k\u00fcrtaj\u0131 ima eden veya m\u00fcstehcen belgeler veya \u00e7izimler kullanamaz.<\/p>\n<\/blockquote>\n\n\n\n<p>\u0130la\u00e7 Makinesi Yasas\u0131, Madde 66&#8217;da, yukar\u0131da belirtildi\u011fi gibi &#8220;yan\u0131lt\u0131c\u0131 veya abart\u0131l\u0131 ifadeleri&#8221; &#8220;reklam&#8221; yapmay\u0131 yasaklar. Bu nedenle, t\u0131bbi cihazlar\u0131n reklamlar\u0131n\u0131 yay\u0131nlarken, bu duruma d\u00fc\u015fmemeye dikkat etmek gerekmektedir.<\/p>\n\n\n\n<p>&#8220;Yan\u0131lt\u0131c\u0131 veya abart\u0131l\u0131 ifadeler&#8221;, ger\u00e7e\u011fe ayk\u0131r\u0131 ifadeler veya abart\u0131l\u0131 ifadelerle t\u00fcketicilere yan\u0131lt\u0131c\u0131 bir alg\u0131 olu\u015fturma riski olan reklamlar\u0131 ifade eder. Peki, somut olarak hangi a\u00e7\u0131klamalar bu duruma girer? Bu, soyut ve anla\u015f\u0131lmas\u0131 zor gibi g\u00f6r\u00fcnebilir.<\/p>\n\n\n\n<p>Bu somut de\u011ferlendirme hakk\u0131nda, Japon Sa\u011fl\u0131k, \u00c7al\u0131\u015fma ve Refah Bakanl\u0131\u011f\u0131, &#8220;\u0130la\u00e7lar vb. \u0130\u00e7in Uygun Reklam Standartlar\u0131 Hakk\u0131nda&#8221; (Heisei 29 y\u0131l\u0131 (2017) 29 Eyl\u00fcl tarihli Japon Sa\u011fl\u0131k, \u00c7al\u0131\u015fma ve Refah Bakanl\u0131\u011f\u0131 \u0130la\u00e7 ve Ya\u015fam Hijyeni B\u00fcrosu Bildirisi) belirtilen standartlar\u0131 belirlemi\u015ftir. Ve Japon Sa\u011fl\u0131k, \u00c7al\u0131\u015fma ve Refah Bakanl\u0131\u011f\u0131, bu standartlar\u0131n uygulanmas\u0131nda, a\u00e7\u0131klamalar ve dikkat edilmesi gereken hususlar\u0131 da yay\u0131nlam\u0131\u015ft\u0131r. Pratikte, bu bildiriye g\u00f6re reklam g\u00f6sterimleri d\u00fc\u015f\u00fcn\u00fcl\u00fcr.<\/p>\n\n\n\n<p>\u00d6rne\u011fin, t\u0131bbi cihazlar s\u00f6z konusu oldu\u011funda, &#8220;\u25cb\u25cb&#8217;yi \u00f6nler&#8221; \u015feklinde bir etkinlik ve etki i\u00e7in onay al\u0131nm\u0131\u015fsa, sadece &#8220;\u25cb\u25cb&#8217;ye&#8221; gibi ifadeler kabul edilmez. Yani, &#8220;cilt tahri\u015fini \u00f6nler&#8221; \u015feklinde bir ifade i\u00e7in onay al\u0131nm\u0131\u015fsa, &#8220;cilt tahri\u015fine&#8221; veya &#8220;cilt tahri\u015fine iyi gelir&#8221; gibi ifadeler kabul edilmez. Bu \u015fekilde, olduk\u00e7a somut bir k\u0131lavuz oldu\u011fu g\u00f6r\u00fclebilir.<\/p>\n\n\n\n<p>Japon Sa\u011fl\u0131k, \u00c7al\u0131\u015fma ve Refah Bakanl\u0131\u011f\u0131, bu standartlara uygun olarak yasall\u0131k de\u011ferlendirmesi yapmaktad\u0131r. Bu standartlara ayk\u0131r\u0131 hareket edilmesi durumunda, rehberlik alabilir veya para cezas\u0131 \u00f6deme emri alabilirsiniz, bu nedenle dikkatli olunmas\u0131 gerekmektedir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Tanimi_Ilac_Disi_Urunler\"><\/span>Tan\u0131m\u0131 \u0130la\u00e7 D\u0131\u015f\u0131 \u00dcr\u00fcnler<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/monolith.law\/wp-content\/uploads\/2020\/05\/9-1024x704.jpg\" alt=\"\" class=\"wp-image-10143\" \/><\/figure>\n\n\n\n<p>\u00d6nceden belirtti\u011fimiz operasyon standartlar\u0131nda, ila\u00e7lar, ila\u00e7 d\u0131\u015f\u0131 \u00fcr\u00fcnler ve kozmetikler farkl\u0131 \u015fekillerde ele al\u0131nmaktad\u0131r. \u00d6rne\u011fin, kozmetiklerde farmakolojik etkileri belirtmek yasakt\u0131r, ancak ila\u00e7 d\u0131\u015f\u0131 \u00fcr\u00fcnlerde belirtilebilir. &#8220;Bitkisel ila\u00e7 kar\u0131\u015f\u0131m\u0131&#8221; ifadesi, ila\u00e7 d\u0131\u015f\u0131 \u00fcr\u00fcnlerde, onaylanm\u0131\u015f etkinlik ve etkilerle ili\u015fkili oldu\u011funda kabul edilebilir, ancak kozmetiklerde genellikle kabul edilmez.<\/p>\n\n\n\n<p>Peki, Japon \u0130la\u00e7lar ve T\u0131bbi Cihazlar Yasas\u0131&#8217;nda (Pharmaceuticals and Medical Devices Act) ila\u00e7 d\u0131\u015f\u0131 \u00fcr\u00fcnler neyi ifade eder? Bu, Japon \u0130la\u00e7lar ve T\u0131bbi Cihazlar Yasas\u0131&#8217;nda tan\u0131mlanm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote\">\n<p>Japon \u0130la\u00e7lar ve T\u0131bbi Cihazlar Yasas\u0131 Madde 2, F\u0131kra 2 \u0130la\u00e7 D\u0131\u015f\u0131 \u00dcr\u00fcnlerin Tan\u0131m\u0131 (Madde 2, F\u0131kra 2)<br> Bu yasada &#8220;ila\u00e7 d\u0131\u015f\u0131 \u00fcr\u00fcnler&#8221;, a\u015fa\u011f\u0131da belirtilen ve insan v\u00fccuduna kar\u015f\u0131 hafif etkisi olan maddeleri ifade eder.<br> 1. A\u015fa\u011f\u0131daki ama\u00e7lar i\u00e7in kullan\u0131lan ve makine veya alet olmayan maddeler (bu kullan\u0131m ama\u00e7lar\u0131n\u0131n yan\u0131 s\u0131ra, ayn\u0131 zamanda \u00f6nceki f\u0131kran\u0131n (2) veya (3) numaral\u0131 maddesinde belirtilen ama\u00e7lar i\u00e7in kullan\u0131lan maddeler hari\u00e7).<br> A. Mide bulant\u0131s\u0131 ve di\u011fer rahats\u0131zl\u0131klar\u0131n veya a\u011f\u0131z veya v\u00fccut kokusunun \u00f6nlenmesi<br> B. Pi\u015fik, tahri\u015f vb. \u00f6nleme<br> C. Sa\u00e7 d\u00f6k\u00fclmesinin \u00f6nlenmesi, sa\u00e7 b\u00fcy\u00fcmesi veya t\u00fcy d\u00f6kme<br> 2. \u0130nsan veya hayvan sa\u011fl\u0131\u011f\u0131n\u0131 korumak i\u00e7in kullan\u0131lan ve makine veya alet olmayan maddeler (fareler, sinekler, sivrisinekler, bitler ve benzeri canl\u0131lar\u0131n kontrol\u00fc i\u00e7in kullan\u0131lan maddeler) (bu kullan\u0131m ama\u00e7lar\u0131n\u0131n yan\u0131 s\u0131ra, ayn\u0131 zamanda \u00f6nceki f\u0131kran\u0131n (2) veya (3) numaral\u0131 maddesinde belirtilen ama\u00e7lar i\u00e7in kullan\u0131lan maddeler hari\u00e7).<br> 3. \u00d6nceki f\u0131kran\u0131n (2) veya (3) numaral\u0131 maddesinde belirtilen ama\u00e7lar i\u00e7in kullan\u0131lan maddeler (\u00f6nceki madde 2&#8217;de belirtilen maddeler hari\u00e7) aras\u0131nda, Sa\u011fl\u0131k, \u00c7al\u0131\u015fma ve Refah Bakan\u0131 taraf\u0131ndan belirlenenler.<\/p>\n<\/blockquote>\n\n\n\n<p>Bu maddede, &#8220;\u00f6nceki f\u0131kran\u0131n (2) veya (3) numaral\u0131 maddesinde belirtilen&#8230;&#8221; ifadesi ge\u00e7mektedir, bu \u00f6nceki f\u0131kra yani Japon \u0130la\u00e7lar ve T\u0131bbi Cihazlar Yasas\u0131 Madde 2, F\u0131kra 1&#8217;i ifade eder ve bu ila\u00e7lar\u0131n tan\u0131m\u0131d\u0131r.<\/p>\n\n\n\n<p>Yani, &#8220;ila\u00e7 d\u0131\u015f\u0131 \u00fcr\u00fcnler&#8221;, ila\u00e7lardan daha hafif bir etkisi olan ancak insan v\u00fccuduna bir t\u00fcr tedavi veya iyile\u015ftirme etkisi sa\u011flayan maddeleri ifade eder. Ayr\u0131ca, hayvanlar\u0131n kontrol\u00fc i\u00e7in kullan\u0131lan maddeler de dahildir.<\/p>\n\n\n\n<p>&#8220;\u0130la\u00e7lar&#8221;, &#8220;ila\u00e7 d\u0131\u015f\u0131 \u00fcr\u00fcnler&#8221; ve &#8220;kozmetikler&#8221; aras\u0131ndaki ayr\u0131m hakk\u0131nda, a\u015fa\u011f\u0131daki makaleye bak\u0131n\u0131z.<\/p>\n\n\n\n<p>\u0130lgili Makale: <a href=\"https:\/\/monolith.law\/corporate\/pharmaceutical-affairs-law\" target=\"_blank\" rel=\"noreferrer noopener\">&#8220;\u0130la\u00e7lar&#8221;, &#8220;\u0130la\u00e7 D\u0131\u015f\u0131 \u00dcr\u00fcnler&#8221; ve &#8220;Kozmetikler&#8221; Nas\u0131l Ay\u0131rt Edilir?[ja]<\/a><\/p>\n\n\n\n<p>\u00d6zellikle, antiseptikler, ba\u011f\u0131rsak d\u00fczenleyiciler, vitamin takviyeleri gibi geni\u015f bir yelpazede \u00fcr\u00fcnler ila\u00e7 d\u0131\u015f\u0131 \u00fcr\u00fcnler kapsam\u0131na girer. Tokyo Metropolitan Health and Safety Research Center HP web sitesinde bir liste bulunmaktad\u0131r, l\u00fctfen ona da g\u00f6z at\u0131n\u0131z.<\/p>\n\n\n\n<p>\u0130la\u00e7 d\u0131\u015f\u0131 \u00fcr\u00fcnler, Sa\u011fl\u0131k, \u00c7al\u0131\u015fma ve Refah Bakan\u0131&#8217;n\u0131n onay\u0131n\u0131 gerektirir ve bu onay\u0131 alan \u00fcr\u00fcnler, etkin maddeleri vb. g\u00f6stererek sat\u0131\u015f yapabilirler.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%E3%80%8C%E5%8C%BB%E8%96%AC%E9%83%A8%E5%A4%96%E5%93%81%E3%80%8Dnin_Reklam_Ifadeleri_Duzenlemesi\"><\/span>\u300c\u533b\u85ac\u90e8\u5916\u54c1\u300dnin Reklam \u0130fadeleri D\u00fczenlemesi<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/monolith.law\/wp-content\/uploads\/2020\/05\/7-1024x576.jpg\" alt=\"\" class=\"wp-image-10141\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%E3%80%8CReklam%E3%80%8Din_Tanimi\"><\/span>\u300cReklam\u300d\u0131n Tan\u0131m\u0131<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>\u00d6nceden bahsetti\u011fimiz 66. maddeyi al\u0131nt\u0131layarak, Japon \u0130la\u00e7 Hukuku&#8217;nun (\u85ac\u6a5f\u6cd5) &#8220;yan\u0131lt\u0131c\u0131 veya abart\u0131l\u0131 ifadeleri&#8221; &#8220;reklam&#8221; yapmay\u0131 yasaklad\u0131\u011f\u0131n\u0131 belirtmi\u015ftik. Bu konuyu daha detayl\u0131 inceleyece\u011fiz.<br>\nReklam, \u00d6d\u00fcl G\u00f6sterim Yasas\u0131 (\u666f\u54c1\u8868\u793a\u6cd5) gibi durumlarda da sorun olabilir, ancak \u0130la\u00e7 Hukuku ile ilgili durumda tan\u0131m\u0131,<\/p>\n\n\n\n<p>&#8220;Heisei 10 y\u0131l\u0131nda (1998) 29 Eyl\u00fcl tarihinde \u0130la\u00e7 G\u00fcvenli\u011fi B\u00fcrosu Denetim ve Y\u00f6nlendirme B\u00f6l\u00fcm\u00fc Ba\u015fkan\u0131 taraf\u0131ndan yay\u0131nlanan 148 numaral\u0131 bildiri&#8221; ile belirlenmi\u015ftir. Buna g\u00f6re,<\/p>\n\n\n\n<blockquote class=\"wp-block-quote\">\n<p>1 M\u00fc\u015fteriyi \u00e7ekme (m\u00fc\u015fterinin sat\u0131n alma iste\u011fini art\u0131rma) niyetinin a\u00e7\u0131k olmas\u0131<br> 2 Belirli bir ila\u00e7 vb. \u00fcr\u00fcn\u00fcn ad\u0131n\u0131n a\u00e7\u0131k\u00e7a belirtilmi\u015f olmas\u0131<br> 3 Genel halk\u0131n fark\u0131nda olabilece\u011fi bir durumda olmas\u0131<\/p>\n<\/blockquote>\n\n\n\n<p>Bu 1-3 aras\u0131 gerekliliklerin t\u00fcm\u00fcn\u00fc kar\u015f\u0131lad\u0131\u011f\u0131nda, bu bir reklam olarak kabul edilir.<\/p>\n\n\n\n<p>Ve bu bildiride<\/p>\n\n\n\n<blockquote class=\"wp-block-quote\">\n<p>Madde 2 (Hedef al\u0131nan reklamlar)<br> Bu standart, gazete, dergi, televizyon, radyo, web sitesi ve sosyal a\u011f hizmetleri vb. t\u00fcm medya reklamlar\u0131n\u0131 hedef al\u0131r.<\/p>\n<\/blockquote>\n\n\n\n<p>Belirtilmi\u015ftir. Yani, d\u0131\u015far\u0131ya as\u0131lan bir tabela, gazete reklam\u0131, televizyon reklam\u0131, sokak afi\u015fi ve internet \u00fczerindeki reklamlar da dahil olmak \u00fczere. Web sitesi \u00fczerindeki banner reklamlar veya e-posta b\u00fcltenleri de genel halk\u0131n fark\u0131nda olabilece\u011fi bir durumda oldu\u011fu i\u00e7in, 1-3&#8217;e uygundur.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Reklami_Duzenlenen_Taraflar\"><\/span>Reklam\u0131 D\u00fczenlenen Taraflar<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>\u0130la\u00e7 Hukuku&#8217;nun 66. maddesinin 1. f\u0131kras\u0131ndan 3. f\u0131kras\u0131na kadar, &#8220;herhangi bir ki\u015fi&#8221; ifadesi bulunmaktad\u0131r. Bu, \u00fcreticiler, sat\u0131c\u0131lar, reklam yay\u0131nlayan medya vb. herkesi kapsar.<\/p>\n\n\n\n<p>\u00d6rne\u011fin, kozmetik \u00fcreticisi A, televizyon kanal\u0131 B&#8217;ye bir televizyon reklam\u0131 yay\u0131nlama talebinde bulunmu\u015f ancak bu reklam yasaklanm\u0131\u015f bir reklama dahil olmu\u015fsa, hem A hem de B ihlal eden taraflar olur ve cezai yapt\u0131r\u0131mlara tabi olurlar.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Hangi_Ifadeler_%E2%80%9CAbartili%E2%80%9D_Olarak_Kabul_Edilir\"><\/span>Hangi \u0130fadeler &#8220;Abart\u0131l\u0131&#8221; Olarak Kabul Edilir?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Hangi ifadelerin yan\u0131lt\u0131c\u0131 veya abart\u0131l\u0131 ifadelere dahil oldu\u011fu, daha \u00f6nce bahsetti\u011fimiz operasyon standartlar\u0131 ile belirlenmi\u015ftir.<\/p>\n\n\n\n<p>Bu standart, \u0130la\u00e7 Hukuku&#8217;nun 66. maddesinin 1. f\u0131kras\u0131n\u0131 somutla\u015ft\u0131r\u0131r. Ve 66. madde, &#8220;Reklam\u0131n i\u00e7eri\u011finin, yan\u0131lt\u0131c\u0131 veya abart\u0131l\u0131 olmamas\u0131n\u0131 sa\u011flamak ve yan\u0131lt\u0131c\u0131 reklamlar\u0131 ortadan kald\u0131rmak, genel t\u00fcketicilerin ila\u00e7lar vb. hakk\u0131nda yanl\u0131\u015f bir anlay\u0131\u015fa sahip olmamas\u0131n\u0131 sa\u011flamak ve reklamlar\u0131n d\u00fczg\u00fcnle\u015ftirilmesini sa\u011flamak&#8221; amac\u0131yla yerle\u015ftirilmi\u015ftir.<\/p>\n\n\n\n<p>Ve bu kararda, bildirinin a\u00e7\u0131klamas\u0131nda, &#8220;Bir reklam\u0131n ihlal eden bir reklam olup olmad\u0131\u011f\u0131 de\u011ferlendirmesi, bu a\u00e7\u0131klama ve dikkat edilmesi gereken hususlar vb. i\u00e7inde belirtilen \u00f6rnekler ve metinlerden sadece bi\u00e7imsel olarak de\u011ferlendirilmemeli, \u00e7e\u015fitli unsurlar\u0131n t\u00fcm\u00fc dikkate al\u0131narak de\u011ferlendirilmelidir&#8221; denmi\u015ftir, yani her durum tek tip de\u011fil, bireysel olarak de\u011ferlendirilir.<\/p>\n\n\n\n<p>\u0130\u015fletmelerde de, reklam yaparken, sadece bu standartlara bi\u00e7imsel olarak ayk\u0131r\u0131 olup olmad\u0131\u011f\u0131na de\u011fil, yasalar\u0131n amac\u0131na g\u00f6re dikkatli bir \u015fekilde de\u011ferlendirilmesi gerekmektedir.<\/p>\n\n\n\n<p>Ayr\u0131ca, ila\u00e7 d\u0131\u015f\u0131 \u00fcr\u00fcnler ve kozmetikler hakk\u0131nda, Japon Kozmetik Sanayi Birli\u011fi (\u65e5\u672c\u5316\u7ca7\u54c1\u5de5\u696d\u9023\u5408\u4f1a) adl\u0131 bir kurulu\u015f, &#8220;Kozmetiklerin Uygun Reklam K\u0131lavuzu&#8221; adl\u0131 bir \u00f6z-denetim kural\u0131 belirlemi\u015ftir. L\u00fctfen bunu da kontrol edin.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ozet\"><\/span>\u00d6zet<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>\u0130la\u00e7 d\u0131\u015f\u0131 \u00fcr\u00fcnler, ila\u00e7lar ve kozmetikler aras\u0131nda konumland\u0131r\u0131lan ve g\u00fcnl\u00fck olarak kullan\u0131labilen \u00fcr\u00fcnlerdir. Ancak, ila\u00e7 bile\u015fenlerini i\u00e7erdi\u011fi i\u00e7in genellikle kozmetiklerden daha etkilidirler, bu y\u00fczden reklam ve etiketlemeleri dikkatlice yap\u0131lmal\u0131d\u0131r.<\/p>\n\n\n\n<p>Reklam ve etiketleme konusunda, Japon Sa\u011fl\u0131k, \u00c7al\u0131\u015fma ve Refah Bakanl\u0131\u011f\u0131&#8217;ndan (Japanese Ministry of Health, Labour and Welfare) detayl\u0131 y\u00f6nergeler bulunmaktad\u0131r, ancak bu kararlar her zaman kolay olmayabilir. <br> Bir i\u015fe ba\u015flarken veya bir \u00fcr\u00fcn satarken belirsizlikleriniz varsa, hukuk uzman\u0131 bir avukata dan\u0131\u015fmak ve onun karar\u0131na ba\u015fvurmak en g\u00fcvenli yol olacakt\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00d6rne\u011fin &#8220;medicinal cosmetics&#8221; gibi \u00fcr\u00fcnlerin \u00fcretimi ve sat\u0131\u015f\u0131, her \u00fcr\u00fcn i\u00e7in Japon Sa\u011fl\u0131k, \u00c7al\u0131\u015fma ve Refah Bakan\u0131&#8217;n\u0131n onay\u0131n\u0131 gerektirir. Bir inceleme s\u00fcrecinden ge\u00e7tikten ve onay  [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":63937,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[30,24],"acf":[],"_links":{"self":[{"href":"https:\/\/monolith.law\/tr\/wp-json\/wp\/v2\/posts\/61065"}],"collection":[{"href":"https:\/\/monolith.law\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/monolith.law\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/monolith.law\/tr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/monolith.law\/tr\/wp-json\/wp\/v2\/comments?post=61065"}],"version-history":[{"count":4,"href":"https:\/\/monolith.law\/tr\/wp-json\/wp\/v2\/posts\/61065\/revisions"}],"predecessor-version":[{"id":64116,"href":"https:\/\/monolith.law\/tr\/wp-json\/wp\/v2\/posts\/61065\/revisions\/64116"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/monolith.law\/tr\/wp-json\/wp\/v2\/media\/63937"}],"wp:attachment":[{"href":"https:\/\/monolith.law\/tr\/wp-json\/wp\/v2\/media?parent=61065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/monolith.law\/tr\/wp-json\/wp\/v2\/categories?post=61065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/monolith.law\/tr\/wp-json\/wp\/v2\/tags?post=61065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}